DIALOG(R) File 351: Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

007094652

WPI Acc No: 1987-094649/\*198714\*

XRAM Acc No: C87-039355

Treating chronic graft-host reactions and autoimmune diseases - esp. systemic Lupus erythematosus, by admin. of

5-methyl-isoxazole-4-carboxylic acid anilide or its metabolite

Patent Assignee: HOECHST AG (FARH ); BAYER AG (FARB )

Inventor: BARTLETT R R; KAEMMERER F; SCHLEYERBACH R; KAMMERER F J;

SCHLEYERBA R

Number of Countries: 019 Number of Patents: 023

Patent Family:

tent ramily								
tent No	Kind	Date		plicat No	Kind	Date	Week	
3534440	Α	19870402	DE	3534440	Α	19850927	198714	В
217206	Α	19870408	ΕP	86112687	Α	19860913	198714	
62072614	Α	19870403	JP	86226368	Α	19860926	198719	
8663167	Α	19870402					198725	
8607347	Α	19870324	ZA	867347	Α	19860926	198727	
2001996	Α	19880701	ES	862206	Α	19860926	198924	
4965276	Α	19901023	US	86911328	Α	19860925	199045	
1275251	С	19901016					199047	
80149	Α	19901129					199105	
559238	A1	19930908	ΕP	86112687	Α	19860913	199336	
			EP	93106367	Α	19860913		
5208908	Α	19930820	JP	86226368	Α	19860926	199338	
			JP	92322998	Α	19860926		
217206	B1	19931103			Α	19860913	199344	
3689252	G	19931209	DE	3689252	Α	19860913	199350	
			ΕP	86112687	Α	19860913		
5268382	Α	19931207	US	86911328	Α	19860925	199350	
			US	90575603	A	19900831		
			US	92870327	Α	19920417		
95029918	B2	19950405	JP	86226368	Α	19860926	199518	
					Α	19860926		
559238	B1	19950503	ΕP	86112687	Α	19860913	199522	
			EP	93106367	Α	19860913		
3650315	G	19950608	DE	3650315	Α	19860913	199528	
			EP	93106367	A	19860913		
7165694	Α	19950627	JP	86226368	Α	19860926	199534	
			JP	94219865	A	19860926		
5459163	Α	19951017	US	86911328	A	19860925	199547	
			US	90575603	Α	19900831		
			US	92870327	Α	19920417		
			US	93119840	Α	19930913		
2514190	B2	19960710	JP	86226368	Α	19860926	199632	
2607848	B2	19970507	JP	86226368	Α	19860926	199723	
			JP	94219865	Α	19860926		
5679709	Α	19971021			Α	19860925	199748	
			US	90575603	Α	19900831		
			US	92870327	Α	19920417		
			US	93119840	Α	19930913		
			US	95478847	Α	19950607		
1100652	A3	19980428	BR	971100652	A	19970507	199823	
	217206 3689252 5268382 95029918 559238 3650315 7165694 5459163 2514190 2607848 5679709	217206 B1 3689252 G 5268382 A  95029918 B2 559238 B1 3650315 G 7165694 A 5459163 A  2514190 B2 2607848 B2 5679709 A	217206 3689252 G 19931209 5268382 A 19931207  95029918 B2 19950405 559238 B1 19950503 3650315 G 19950608 7165694 A 19950627 5459163 A 19951017  2514190 2607848 B2 19970507 5679709 A 19971021	JP   217206	JP 92322998	JP 92322998	JP 92322998	The color of the

```
Priority Applications (No Type Date): DE 3534440 A 19850927
Cited Patents: 5.Jnl.Ref; A3...8924; EP 13376; EP 257882; No-SR.Pub; DE
  2555789; US 4061767; US 4284786
Patent Details:
Patent No Kind Lan Pg
                         Main IPC
                                     Filing Notes
DE 3534440
              Α
              A G
EP 217206
   Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE
US 4965276
              Α
                    10
EP 559238
              A1 G 13 C07C-255/23
                                     Related to application EP 86112687
   Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE
JP 5208908
                     8 A61K-031/275 Div ex application JP 86226368
EP 217206
              B1 G 14 A61K-031/42
   Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE
                                     Based on patent EP 217206
DE 3689252
             G
                       A61K-031/42
US 5268382
              Α
                    10 A61K-031/42
                                     Div ex application US 86911328
                                     Cont of application US 90575603
                                     Div ex patent US 4965276
JP 95029918
              B2
                     8 A61K-031/275
                                     Div ex application JP 86226368
                                     Based on patent JP 5208908
EP 559238
                     6 C07C-255/23
              B1 G
                                     Related to application EP 86112687
   Designated States (Regional): AT BE CH DE FR GB IT LI LU NL SE
DE 3650315
              G
                       C07C-255/23
                                     Based on patent EP 559238
JP 7165694
                     7 C07C-255/23
                                     Div ex application JP 86226368
              Α
US 5459163
              Α
                       A61K-031/42
                                     Div ex application US 86911328
                                     Cont of application US 90575603
                                     Div ex application US 92870327
                                     Div ex patent US 4965276
                                     Div ex patent US 5268382
JP 2514190
              B2
                     9 A61K-031/275
                                     Previous Publ. patent JP 62072614
JP 2607848
              B2
                     7 C07C-255/23
                                     Div ex application JP 86226368
                                     Previous Publ. patent JP 7165694
US 5679709
              Α
                    10 A61K-031/275
                                     Div ex application US 86911328
                                     Cont of application US 90575603
                                     Div ex application US 92870327
                                     Div ex application US 93119840
                                     Div ex patent US 4965276
                                     Div ex patent US 5268382
                                     Div ex patent US 5459163
BR 1100652
                       C07C-255/23
              A3
```

## Abstract (Basic): DE 3534440 A

The use of amides of formulae (I) and (II), or the salts of (II), to make pharmaceuticals for treating chronic graft-host diseases and autoimmune diseases is new. Pref. oral formulations contain 10-200, esp. 50-100, mg (I) or (II); intra-venous formulations contain 1-30, esp. 5-10, mg, and rectal formulations contain 50-300, esp. 100-200 mg.

USE/ADVANTAGE - (I) is already known (EP 13376) as an anti-inflammatory. It, and its metabolite (II) (Ann. Rept. Med. Chem., 18 (1983) 171), are now found to be immunomodulators, so are useful for preventing transplant rejection and particularly for treating systemic lupus erythematosus. Unlike known immuno-suppressants, they do not induce a general suppression of the immune system, so allow recovery of reduced T-cell function. For adults, the pref. daily dose is 50 - 200 mg orally; 10 - 30 mg intravenously and 100 - 300 mg rectally.

(Dwq.0/5)

Title Terms: TREAT; CHRONIC; GRAFT; HOST; REACT; AUTO; IMMUNE; DISEASE; SYSTEMIC; LUPUS; ERYTHEMATOSUS; ADMINISTER; METHYL; ISOXAZOLE; CARBOXYLIC; ACID; ANILIDE; METABOLITE

Derwent Class: B03; B05

International Patent Class (Main): A61K-031/275; A61K-031/42; C07C-255/23

International Patent Class (Additional): A61K-031/16; A61K-031/36;

A61K-031/425; C07C-121/41; C07C-255/24; C07D-261/18

File Segment: CPI